- Previous Close
0.6050 - Open
0.6150 - Bid 0.6150 x --
- Ask 0.6550 x --
- Day's Range
0.6150 - 0.6550 - 52 Week Range
0.4560 - 0.7550 - Volume
10 - Avg. Volume
100 - Market Cap (intraday)
2.376B - Beta (5Y Monthly) 0.79
- PE Ratio (TTM)
8.19 - EPS (TTM)
0.0800 - Earnings Date Mar 12, 2025
- Forward Dividend & Yield 0.03 (4.91%)
- Ex-Dividend Date Apr 14, 2025
- 1y Target Est
--
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products. In addition, the company provides bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage. The company has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited. The company was incorporated in 1995 and is based in Central, Hong Kong.
www.grandpharm.com11,987
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: MX6A.F
View MorePerformance Overview: MX6A.F
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MX6A.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MX6A.F
View MoreValuation Measures
Market Cap
2.19B
Enterprise Value
2.34B
Trailing P/E
7.52
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.59
Price/Book (mrq)
1.13
Enterprise Value/Revenue
1.76
Enterprise Value/EBITDA
5.80
Financial Highlights
Profitability and Income Statement
Profit Margin
21.20%
Return on Assets (ttm)
5.84%
Return on Equity (ttm)
15.51%
Revenue (ttm)
11.64B
Net Income Avi to Common (ttm)
2.47B
Diluted EPS (ttm)
0.0800
Balance Sheet and Cash Flow
Total Cash (mrq)
3.73B
Total Debt/Equity (mrq)
26.90%
Levered Free Cash Flow (ttm)
683.25M